TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Prolonged procedure time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increase in ADCC antibody responses against the vaccine strain TX12
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Patient adherence to the self-monitoring program
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Uptake of cervical cancer screening
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: diabetes symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Decrease in LM ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Feeding tolerance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Remission of illness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: overall ratings
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in BMI post surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Identification of tracheal versus bronchial intubation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Flap performance based on the Global Rating Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Confidence to perform rhomboid flaps
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: hydroxyvitamin D levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Performance on CUS procedure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: GRS 3 scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Stress levels among trainees
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Reduction of ulcer area
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Mean test scores on the Objective Structured Clinical Examination
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: reduction in bacterial colonies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: reduction in plaque index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: reduction in gingival index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Passive stiffness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Isometric muscle force
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: strategy success
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: in-stent late lumen loss at 9 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: H. pylori cure rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risk of stroke at 18 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Release of EMPs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Viability of HUVECs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Apoptosis of HUVECs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall perception scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Cardiovascular (CV) death
Endpoint domain: Mortality/survival
Primary endpoint: Cholesterol concentration of HDL-2 subclass
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Cholesterol concentration of HDL-3 subclass
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Ratios of enzyme activities to LDL-C levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Nitrotyrosine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy rate of submucosal injection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Adverse events related to submucosal injection
Endpoint domain: Adverse events/effects
Primary endpoint: visual analog scale values
Endpoint domain: Life impact
Endpoint subdomain: Pain
Primary endpoint: recurrent cholecystitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Mouthing episodes of inedible parts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: subjective cognitive impairment
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Triple therapy efficacy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Skin dryness scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Scratch mark scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Skin conductance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Incidence of major, minor, or clinically relevant bleeding
Endpoint domain: Adverse events/effects
Primary endpoint: VF-14 improvement
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: investigator's evaluation of fine lines
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: overall photoaging
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: self‐evaluation of skin condition
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: HbA1c level change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Plasma lidocaine concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean heart rate increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: response rate to pioglitazone treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Need for vasoactive medication (norepinephrine)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Incremental Shuttle Walk
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC for DIN test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in composite IML stain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 7 day point prevalence of self-reported abstinence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: QHI values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fecal fat loss expressed as percent of fat intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: percentage of patients reporting complete recovery or much improvement
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: minimum diastolic arterial blood flow velocity (DV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: maximum systolic arterial blood flow velocity (SV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Symptom intensity score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: nutrition activity score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cumulative probability of treatment failure
Endpoint domain: Mortality/survival
Primary endpoint: Completion of PEP without grade 3 or 4 AEs
Endpoint domain: Adverse events/effects
Primary endpoint: Day-long glycemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Insulin secretion during meal test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Insulin sensitivity (ΔHOMA-IR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Sleeping hours
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Wake frequency
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: SSS grades
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: rate of complete necrosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean change of serum TC
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Mean change of serum LDL-C
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Total RFS score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total RSI score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vocal cord oedema improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in HCV RNA level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean decision delivery interval
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: duration of admission
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: improved drinking outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: blood triglyceride concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: new onset asthma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Overall risk of cancer
Endpoint domain: Mortality/survival
Primary endpoint: Respiratory cancer risk
Endpoint domain: Mortality/survival
Primary endpoint: subjective drowsiness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Correlation of TT and ROTEM parameters with plasma concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: redisplacement of fractures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: angulation of fractures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Urease activity in mouth cavity microflora
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: L-FMC (flow-mediated constriction)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: FMD (flow-mediated dilation)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Mental symptoms (Kupperman index)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of life (QOL scores)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Reduction in elevated blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Reduction in LDL levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Identification of asymptomatic PAD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Arrhythmia-free cases
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complete PV isolation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: clinical efficacy rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Symptoms of peripheral neuropathy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Incidence of local recurrence at 2 years
Endpoint domain: Mortality/survival
Primary endpoint: Median time to first local recurrence
Endpoint domain: Mortality/survival
Primary endpoint: symptomatic experiences
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in Lysholm score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in Tegner score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in IKDC score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: wheeze exacerbation rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: lung function improvements (FEV1 and FEF(25-75))
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Risk of SVS
Endpoint domain: Mortality/survival
Primary endpoint: Percentage of responders (≥30% decrease in 'off' time)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean corpuscular volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Erythropoietin maintenance dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative nausea/vomiting scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Throat pain scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Urinary AcSDKP excretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma active renin concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 24-h ambulatory blood pressure reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Local relapse rate
Endpoint domain: Mortality/survival
Primary endpoint: BML score in the medial tibial plateau
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Grade 3 to 4 anemia
Endpoint domain: Adverse events/effects
Primary endpoint: duration of high-threshold CSP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: high-threshold CSP latency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: mean RIII reflex area
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Concordance between estimated risk and calculated risk
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Cormack‐Lehane score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recovery without complication
Endpoint domain: Adverse events/effects
Primary endpoint: Selenoprotein P levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: eGSHPx levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of 'shell' phenomenon
Endpoint domain: Adverse events/effects
Primary endpoint: Degree of injured vertebra compression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lower mental health problems
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Less use of mental health services
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Less use of psychiatric medication
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Atrial fibrillation-related knowledge
Endpoint domain: Life impact
Endpoint subdomain: null
Primary endpoint: Accuracy of ECG interpretation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in physical activity during sleep
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean body iron increment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Early diastolic inflow velocity in the antero‐posterior transverse direction of the LV
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: PRRD1 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PCT estimates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of ICS refills
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Asthma control levels (ACQ and ACT scores)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Asthma self-efficacy
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Fibromyalgia Impact Questionnaire (FIQ)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Duration of acute confluent mucositis grade 3
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sleep functions
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Speech functions
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: long-term safety and efficacy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage of women achieving prepregnancy weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adverse effects (nausea, diarrhea, hypoglycemia)
Endpoint domain: Adverse events/effects
Primary endpoint: decrease in fasting FFAs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: improvements in fasting adipose tissue insulin sensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Reduction of residents' problem behaviors
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrease in symptoms of depression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrease in symptoms of irritability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean transferrin saturation (TSAT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean serum ferritin concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Childhood obesity prevention and control
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Scapular dyskinesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PSA Doubling Time (DT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total perioperative cost savings
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: mean predose FEV1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: overall satisfaction with asthma medication
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Rate of PLP (phantom limb pain)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in daily ICS dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: visual analogue symptom scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: forced expiratory volume in 1 second (FEV(1))
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: concentration of methacholine provoking a fall in FEV(1) of 20% or more (PC(20))
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Mean R2* values in kidney tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Incidence of diarrhea during chemotherapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Rate of patients requiring a dose reduction or interruption of S‐1
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Onset of kwashiorkor
Endpoint domain: Mortality/survival
Primary endpoint: prevention of cardiovascular events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: elevated levels of fibrin split products and D-dimers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: thromboelastogram index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: blood loss during hours 3, 4, and 5
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: AmB nephrotoxicity
Endpoint domain: Adverse events/effects
Primary endpoint: AUC(0-infinity) for nicotine exposure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: T(max) for nicotine concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: C(max) for nicotine concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of remaining class-II furcations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: IFN-gamma response to human PPD stimulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: sensitivity of exercise test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: specificity of exercise test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: mean difference in percentage fall in FEV1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Catheter failure rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change in insertion length
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes